39
Views
36
CrossRef citations to date
0
Altmetric
Review

Potential Carcinogenicity of Chloral Hydrate–A Review

, , , &
Pages 115-121 | Published online: 25 Sep 2008

References

  • Graham S R, Day R O, Lee R, Fulde GW. Overdose with chloral hydrate: a pharmacological and therapeutic review. Med J Aust 1988; 149: 686–688
  • Cook B A, Bass J W, Nomizu S, Alexander ME. Sedation of children for technical procedures: Current standard of practice. Clin Ped 1992; 31: 137–142
  • Ilkhanipour K, Juels C R, Langdorf MI. Pediatric pain control and conscious sedation: a survey of emergency medicine residencies. Acad Emerg Med 1994; 1: 368–372
  • Committee on Drugs and Committee on Environmental Health, American Academy of Pediatrics. Use of chloral hydrate for sedation in children. Pediatrics 1993; 92: 471–473
  • Nathan J E, Mabanta C Z, Siegel F P. Chloral hydrate's role in pediatric dental sedation. US Pharmacist 1986; 52A–52F
  • Ogino K, Hobara T, Kobayashi H. Comparative study of the tissue distribution of NADH and NADPH-dependent chloral hydrate reducing enzymes in the rat. Bull Environ Contam Toxicol 1990; 44: 377–376
  • Sato A, Nakajima T, Koyama Y. Dose-related effects of a single dose of ethanol on the metabolism in rat liver of some aromatic and chlorinated hydrocarbons. Toxicol Appl Pharmacol 1981; 60: 8–15
  • Kawamoto T, Hobara T, Kobayashi H. The metabolite ratio as a function of chloral hydrate dose and intracellular redox as a function of chloral hydrate dose and intracellular redox state in the perfused rat liver. Pharmacol Toxicol 1987; 60: 325–329
  • Larson L J, Bull RJ. Effect of ethanol on the metabolism of trichloroethylene. J Toxicol Environ Health 1989; 28: 395–406
  • Byington K H, Leibman KC. Metabolism of trichloroethylene in liver microsomes. II. Identification of the reaction product as chloral hydrate. Mol Pharmacol 1965; 1: 247–254
  • Miller R E, Guengerich FP. Oxidation of trichloroethylene by liver microsomal cytochrome P-450: Evidence for chloride migration in a transition state not involving trichloroethylene oxide. Biochemistry 1982; 21: 1090–1097
  • Green T, Prout MS. Species differences in response to trichloroethylene: Biotransformation in rats and mice. Toxicol Appl Pharmacol 1985; 79: 401–411
  • Smith MT. Chloral hydrate warning. Science 1990; 250: 359
  • Carere A, Conti G, Conti L. Assays in Aspergillus nidulans for the induction of forwardmutation in haploid strain 35 and for mitotic nondisjunction, haploidization and crossing-over in diploid strain P1. Progress in Mutation Research, Volume 5: Evaluation of short-term tests for carcinogens, J Ashby, F De Serres, M Draper. Elsevier, AmsterdamThe Netherlands 1985; 307–312
  • Kafer E. Tests which distinguish induced crossing-over and aneuploidy from secondary segregation inAspergillus treated with chloral hydrate or c-rays. Mutat Res 1986; 164: 145–166
  • Furnus C C, Ulrich M A, Terreros M C, Dulout FN. The induction of aneuploidy in cultured chinese hamster cells by propionaldehyde and chloral hydrate. Mutagenesis 1990; 5: 323–326
  • Liang J C, Pacchierotti Cytogenetic F. Investigation of chemically-induced aneuploidy in mouse spermatocytes. Mutat Res 1988; 201: 325–335
  • Russo A, Pacchierotti F, Metalli P. Nondisjunction induced in mouse spermatogenesis by chloral hydrate, a metabolite of trichloroethylene. Environ Mutagen 1984; 6: 695–730
  • Parry J M, Sors A. The detection and assessment of the aneugenic potentiol of environmental chemicals: the European Community Aneuploidy Project. Mutat Res 1993; 287: 3–15
  • Natarajan AT. An overview of the results of testing of known or suspected aneugens using mammalian cells in vitro. Mutat Res 1990; 287: 113–118
  • Heddel J A, Bruce WR. Comparison of tests for mutagenicity or carcinogenicity using assays for sperm abnormalites, formation of mecronuclei and mutations. Salmonella. Origins of Human Cancer, Book C: Human Ris Assessment. Cold Spring Harbour Conferences on Cell proliferation. 1977, H H Hiatt, J D Watson, J A Winsten. Cold Spring Harbour laboratory, Cold Spring Harbour, New yorK, Vol. 4: 1546–1557
  • Waskell L. A study of the mutagenicity of anesthetics and their metabolites. Mutat Res 1978; 57: 141–153
  • Bronzetti G, Bauer C, Cundari E. Genetic and biochemical studies of chloral hydrate, a metabolite of trichloroethylene. Mutat Res 1984; 130: 247
  • Nelson M A, Bull RJ. Induction of strand breaks in DNA by trichloroethylene and metabolites in rat and mouse liver in vivo. Toxicol Appl Phormacol 1988; 94: 45–54
  • Gu Z W, Sele B, Jalbert P. Induction of sister chromatid exchange by trichloroethylene and its metabolites. Toxicol Eur Res 1981; 3: 63–67
  • Salmon A G, Jackson R J, Smith MT. Chloral hydrate: cancer risk assessment of a drug previously presumed safe. The Toxicologist 1991; 11: 350
  • Rannug U, Gothe R, Wachtmeister CA. The mutagenicity of chloroethylene oxide, chloroacetaldehyde, 2-chloroethanol and chloroacetic acid, conceivable metabolites of vinyl chloride. Chem Biol Interactions 1976; 12: 251–263
  • Allen J W, Liang J C, Carrano A V, Preston RJ. Review of literature on chemical-induced aneuploidy in mammalian male germ cells. Mutat Res 1986; 167: 123–137
  • Rijhsinghani K S, Abrahams C, Swerdlow M A. Induction of neoplastic lesions in the livers of C57BLxC3H F1 mice by chloral hydrate. Cancer Detect Prevent 1986; 9: 279–288
  • Roe F JC, Salaman MH. Further studies on incomplete carcinogenesis: Triethylene melamine (T.E.M.), 1,2-Benzanthrancene and β-Propriolactone as initiators of skin tumor formation in the mouse. Brit J Cancer 1955; 9: 177–203
  • Daniel F B, DeAngelo A B, Stober J A, Olson G R, Page NP. Hepatocarcinogenicity of chloral hydrate, 2-chloracetaldehyde, and dichloroacetic acid in the male B6C3F1 mouse. Fundam Appl Toxicol 1992; 19: 156–168
  • Vesseslinovitch S D, Mihailovich N, Rao K VN. Morphology and metastatic nature of induced hepatic nodular lesions in C57BLxC3H F1, mice. Cancer Res 1978; 38: 2003–2010
  • Reimche L D, Sankaran K, Hindmarch K W, Kasian G F, Gorecki D KJ. Chloral hydrate sedation in neonates and infants: clinical and pharmacologic considerations. Dev Pharmacol Ther 1989; 12: 57–64

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.